BrainEver
Matteo Boutte has a diverse range of work experience. Matteo is currently working as a CMC Project Manager at BrainEver since April 2023. Prior to this role, they worked at OSE Immunotherapeutics from November 2021 to June 2023, where they served as a CMC Project Manager and previously as a Chargé d'Assurance Qualité and a Stagiaire Assurance Qualité Opérationnelle CMC. Matteo also worked at Université Paris-Saclay as a Chef de Projet for the Communication du M2 project from October 2019 to October 2020. Matteo gained experience as a Stagiaire Responsable de projet R&D at Agence Générale des Equipements et Produits de Santé (AGEPS) AP-HP from October 2018 to August 2019. Matteo co-founded Junior Etudes Pharmacie Paris V (JEPPV) and served as the Secretary General from September 2016 to June 2018. Matteo also completed internships at Institut Curie - Ensemble hospitalier in June 2017, and at Pharmacie du 5 in May 2016.
Matteo Boutte's education history is as follows:
Matteo Boutte pursued their Master 2 (M2) in Biotechnologie Pharmaceutique et Thérapies Innovantes at Université Paris-Saclay from 2019 to 2020. Prior to that, they completed their Pharmacist degree at Université Paris Cité from 2013 to 2020. During their time at Université Paris Cité, Matteo also earned a Master's degree in Génétique - Immunologie from 2016 to 2018.
In addition to their academic degrees, Matteo holds a Certificat Informatique et Internet from the Ministère chargé de l'Éducation nationale, obtained in 2015. Matteo also obtained a TOEIC score of 975 out of 990 from ETS Global in March 2019.
This person is not in any teams
BrainEver
BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies.